170 related articles for article (PubMed ID: 35819261)
1. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL.
Moser R; Annis J; Nikolova O; Whatcott C; Gurley K; Mendez E; Moran-Jones K; Dorrell C; Sears RC; Kuo C; Han H; Biankin A; Grandori C; Von Hoff DD; Kemp CJ
Cancer Res; 2022 Sep; 82(18):3375-3393. PubMed ID: 35819261
[TBL] [Abstract][Full Text] [Related]
2. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
[TBL] [Abstract][Full Text] [Related]
3. Tetrandrine synergizes with MAPK inhibitors in treating KRAS-mutant pancreatic ductal adenocarcinoma via collaboratively modulating the TRAIL-death receptor axis.
Tang S; Duan Y; Yuan T; Hu Y; Yuan L; Shen N; Fu Y; Pu C; Wang X; Xu J; Lan X; Zheng Y; Zhou Y; Zhu H; Ding J; Geng M; Huang M
Pharmacol Res; 2023 Nov; 197():106955. PubMed ID: 37820855
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
5. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
[TBL] [Abstract][Full Text] [Related]
6. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF; Uddin MH; Nagasaka M; Fazili F; Al-Hallak MN; Philip PA; El-Rayes B; Azmi AS
Cancer Metastasis Rev; 2021 Sep; 40(3):819-835. PubMed ID: 34499267
[TBL] [Abstract][Full Text] [Related]
8. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer.
Zeng S; Lan B; Ren X; Zhang S; Schreyer D; Eckstein M; Yang H; Britzen-Laurent N; Dahl A; Mukhopadhyay D; Chang D; Kutschick I; Pfeffer S; Bailey P; Biankin A; Grützmann R; Pilarsky C
J Exp Clin Cancer Res; 2022 Aug; 41(1):241. PubMed ID: 35945614
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.
Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
[TBL] [Abstract][Full Text] [Related]
10. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer.
Kumarasamy V; Wang J; Frangou C; Wan Y; Dynka A; Rosenheck H; Dey P; Abel EV; Knudsen ES; Witkiewicz AK
Cancer Res; 2024 Apr; 84(7):1115-1132. PubMed ID: 38294344
[TBL] [Abstract][Full Text] [Related]
11. DIRAS3 induces autophagy and enhances sensitivity to anti-autophagic therapy in KRAS-driven pancreatic and ovarian carcinomas.
Bildik G; Gray JP; Mao W; Yang H; Ozyurt R; Orellana VR; De Wever O; Carey MS; Bast RC; Lu Z
Autophagy; 2024 Mar; 20(3):675-691. PubMed ID: 38169324
[TBL] [Abstract][Full Text] [Related]
12. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract][Full Text] [Related]
13. KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer.
Waters AM; Der CJ
Cold Spring Harb Perspect Med; 2018 Sep; 8(9):. PubMed ID: 29229669
[No Abstract] [Full Text] [Related]
14. Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells.
Chen PY; Muzumdar MD; Dorans KJ; Robbins R; Bhutkar A; Del Rosario A; Mertins P; Qiao J; Schafer AC; Gertler F; Carr S; Jacks T
Cancer Res; 2018 Feb; 78(4):985-1002. PubMed ID: 29279356
[TBL] [Abstract][Full Text] [Related]
15. Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas.
Lenkiewicz E; Malasi S; Hogenson TL; Flores LF; Barham W; Phillips WJ; Roesler AS; Chambers KR; Rajbhandari N; Hayashi A; Antal CE; Downes M; Grandgenett PM; Hollingsworth MA; Cridebring D; Xiong Y; Lee JH; Ye Z; Yan H; Hernandez MC; Leiting JL; Evans RM; Ordog T; Truty MJ; Borad MJ; Reya T; Von Hoff DD; Fernandez-Zapico ME; Barrett MT
Cancer Res; 2020 Oct; 80(20):4324-4334. PubMed ID: 32928922
[TBL] [Abstract][Full Text] [Related]
16. Activation of endogenous retroviruses and induction of viral mimicry by MEK1/2 inhibition in pancreatic cancer.
Cortesi A; Gandolfi F; Arco F; Di Chiaro P; Valli E; Polletti S; Noberini R; Gualdrini F; Attanasio S; Citron F; Ho IL; Shah R; Yen EY; Spinella MC; Ronzoni S; Rodighiero S; Mitro N; Bonaldi T; Ghisletti S; Monticelli S; Viale A; Diaferia GR; Natoli G
Sci Adv; 2024 Mar; 10(13):eadk5386. PubMed ID: 38536927
[TBL] [Abstract][Full Text] [Related]
17. Cell-Autonomous Cxcl1 Sustains Tolerogenic Circuitries and Stromal Inflammation via Neutrophil-Derived TNF in Pancreatic Cancer.
Bianchi A; De Castro Silva I; Deshpande NU; Singh S; Mehra S; Garrido VT; Guo X; Nivelo LA; Kolonias DS; Saigh SJ; Wieder E; Rafie CI; Dosch AR; Zhou Z; Umland O; Amirian H; Ogobuiro IC; Zhang J; Ban Y; Shiau C; Nagathihalli NS; Montgomery EA; Hwang WL; Brambilla R; Komanduri K; Villarino AV; Toska E; Stanger BZ; Gabrilovich DI; Merchant NB; Datta J
Cancer Discov; 2023 Jun; 13(6):1428-1453. PubMed ID: 36946782
[TBL] [Abstract][Full Text] [Related]
18. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in
Fusco MJ; Saeed-Vafa D; Carballido EM; Boyle TA; Malafa M; Blue KL; Teer JK; Walko CM; McLeod HL; Hicks JK; Extermann M; Fleming JB; Knepper TC; Kim DW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250383
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.
Kemp SB; Cheng N; Markosyan N; Sor R; Kim IK; Hallin J; Shoush J; Quinones L; Brown NV; Bassett JB; Joshi N; Yuan S; Smith M; Vostrejs WP; Perez-Vale KZ; Kahn B; Mo F; Donahue TR; Radu CG; Clendenin C; Christensen JG; Vonderheide RH; Stanger BZ
Cancer Discov; 2023 Feb; 13(2):298-311. PubMed ID: 36472553
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
Singh RR; Goldberg J; Varghese AM; Yu KH; Park W; O'Reilly EM
Cancer Treat Rev; 2019 May; 75():27-38. PubMed ID: 30927677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
